The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese

Summary

This study is a open and single center clinical trial in healthy Chinese.The objective of the study is to clarify the pharmacokinetics characteristics and antiplatelet effects of ticagrelor in Chinese and to investigate the impact of genotype.

Timeline

Start

2015-05-20

Primary completion

2015-10-24

Completion

2016-06-16

Publications

• Chen J, Xu G, Xie Z, Xie S, Luo W, Zhong S, Lai W. GPD2 inhibition impairs coagulation function via ROS/NF-kappaB/P2Y12 pathway. Cell Mol Biol Lett. 2025 Jul 18;30(1):84. doi: 10.1186/s11658-025-00759-x.
• Xu G, Liu JE, Liu X, Zhong W, Wang Z, Li H, Xiao X, Chen J, Zhong S, Lai W. DNA methylation mediates the genetic variants on ticagrelor major metabolite elimination and platelet function recovery after ticagrelor discontinuation. Epigenomics. 2022 May;14(10):601-613. doi: 10.2217/epi-2021-0461. Epub 2022 May 16.
• Zhu Q, Zhong W, Wang X, Mai L, He G, Chen J, Tang L, Liu S, Lai W, Zhong S. Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects. Front Pharmacol. 2019 Mar 18;10:209. doi: 10.3389/fphar.2019.00209. eCollection 2019.

Drugs

Indications

No indication recorded.